Observational Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Aug 6, 2020; 8(15): 3259-3266
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3259
Table 3 Sex hormone, lipid, insulin and blood glucose level after three cycles of treatment and biphasic basal body temperature during the treatment
VariablesFAS analysisPPS analysis
BaselineEnd of treatmentP valueBaselineEnd of treatmentP value
FSH (mIU/mL)7.1 ± 3.06.9 ± 2.90.2297.2 ± 3.06.9 ± 2.90.229
LH (mIU/mL)10.4 ± 5.89.6 ± 6.00.09510.8 ± 6.09.6 ± 6.00.095
PRL (mIU/mL)11.3 ± 5.710.9 ± 4.30.44911.4 ± 6.110.9 ± 4.30.449
E2 (mIU/mL)59.7 ± 72.754.7 ± 98.00.80951.9 ± 29.654.7 ± 98.00.809
T (mIU/mL)0.58 ± 0.310.52 ± 0.190.0100.59 ± 0.330.52 ± 0.190.010
DHEA-S (mIU/mL)248.6 ± 114.7231.3 ± 101.70.031248.6 ± 110.8231.3 ± 101.70.031
Patients with biphasic BBT after three cycles of treatment (%, 95%CI)55 (21.2-45.1)55 (21.2-45.1)
TC (mmol/L)4.30 ± 0.804.12 ± 0.860.174.24 ± 0.804.13 ± 0.860.17
TG (mmol/L)1.01 ± 0.591.03 ± 0.470.290.97 ± 0.591.03 ± 0.470.29
HDL (mmol/L)1.02 ± 0.240.99 ± 0.280.541.01 ± 0.240.99 ± 0.280.54
LDL (mmol/L)2.74 ± 0.542.53 ± 0.540.0012.71 ± 0.542.53 ± 0.540.001
Lp (a1)1.04 ± 0.211.25 ± 0.090.781.00 ± 0.211.26 ± 0.090.78
Lp (a2)0.78 ± 0.160.71 ± 0.061.000.79 ± 0.190.71 ± 0.061.00
Insulin (µU/mL)11.3 ± 8.410.5 ± 7.00.04511.7 ± 8.910.5 ± 7.00.045
Glucose (mmol/L)4.9 ± 0.94.7 ± 0.60.424.9 ± 1.14.7 ± 0.60.42